[使用钾竞争酸阻滞剂治疗酸相关疾病]。

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2022-12-25 DOI:10.4166/kjg.2022.143

Yoon Jin Choi

{"title":"[使用钾竞争酸阻滞剂治疗酸相关疾病]。","authors":"Yoon Jin Choi","doi":"10.4166/kjg.2022.143","DOIUrl":null,"url":null,"abstract":"Proton pump inhibitors (PPIs) have several limitations to their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism. Potassium-competitive acid blockers inhibit H+-K+-ATPase in a reversible and K+-competitive manner, are novel acid suppressive drugs with rapid onset of action, meal independence, and prolonged control of intragastric acidity compared to PPIs. Potassium-competitive acid blockers exhibited non-inferior therapeutic efficacies on reflux esophagitis, gastric ulcers, and Helicobacter pylori eradication. The review is focused on the unmet needs across the acid-related diseases and recent updates on clinical studies using vonoprazan and tegoprazan.","PeriodicalId":22736,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"80 6","pages":"247-253"},"PeriodicalIF":0.6000,"publicationDate":"2022-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].\",\"authors\":\"Yoon Jin Choi\",\"doi\":\"10.4166/kjg.2022.143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Proton pump inhibitors (PPIs) have several limitations to their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism. Potassium-competitive acid blockers inhibit H+-K+-ATPase in a reversible and K+-competitive manner, are novel acid suppressive drugs with rapid onset of action, meal independence, and prolonged control of intragastric acidity compared to PPIs. Potassium-competitive acid blockers exhibited non-inferior therapeutic efficacies on reflux esophagitis, gastric ulcers, and Helicobacter pylori eradication. The review is focused on the unmet needs across the acid-related diseases and recent updates on clinical studies using vonoprazan and tegoprazan.\",\"PeriodicalId\":22736,\"journal\":{\"name\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"volume\":\"80 6\",\"pages\":\"247-253\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2022-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4166/kjg.2022.143\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4166/kjg.2022.143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

质子泵抑制剂(PPIs)的疗效有几个局限性，包括酸抑制不足，起效缓慢，由于CYP2C19代谢，患者的疗效不一。钾竞争酸阻滞剂以可逆和钾竞争的方式抑制H+-K+- atp酶，与PPIs相比，是一种新型的抑酸药物，具有起效快、不依赖膳食、对胃内酸度控制时间长等特点。钾竞争性酸阻滞剂在反流性食管炎、胃溃疡和幽门螺杆菌根除方面表现出良好的治疗效果。本综述的重点是酸相关疾病的未满足需求，以及vonoprazan和tegoprazan临床研究的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].

Proton pump inhibitors (PPIs) have several limitations to their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism. Potassium-competitive acid blockers inhibit H⁺-K⁺-ATPase in a reversible and K⁺-competitive manner, are novel acid suppressive drugs with rapid onset of action, meal independence, and prolonged control of intragastric acidity compared to PPIs. Potassium-competitive acid blockers exhibited non-inferior therapeutic efficacies on reflux esophagitis, gastric ulcers, and Helicobacter pylori eradication. The review is focused on the unmet needs across the acid-related diseases and recent updates on clinical studies using vonoprazan and tegoprazan.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Medicine-Medicine (all)

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

24 weeks